Developing a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study
Gallagher, K. M.
MacKenzie, K. R.
Shah, T. T.
Zimmermann, E. F.
Mannas, M. P.
Gómez Rivas, J.
Assmus, M. A.
La Montagna, G.
Boxall, N. E.
Downey, A. P.
Sukhu, T. A.
Chin, Y. F.
Green, J. S. A.
McGrath, J. S.
JournalEuropean urology focus
RightsCopyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
MetadataShow full item record
BACKGROUND: Patient factors associated with urinary tract cancer can be used to risk stratify patients referred with haematuria, prioritising those with a higher risk of cancer for prompt investigation. OBJECTIVE: To develop a prediction model for urinary tract cancer in patients referred with haematuria. DESIGN, SETTING, AND PARTICIPANTS: A prospective observational study was conducted in 10 282 patients from 110 hospitals across 26 countries, aged ≥16 yr and referred to secondary care with haematuria. Patients with a known or previous urological malignancy were excluded. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcomes were the presence or absence of urinary tract cancer (bladder cancer, upper tract urothelial cancer [UTUC], and renal cancer). Mixed-effect multivariable logistic regression was performed with site and country as random effects and clinically important patient-level candidate predictors, chosen a priori, as fixed effects. Predictors were selected primarily using clinical reasoning, in addition to backward stepwise selection. Calibration and discrimination were calculated, and bootstrap validation was performed to calculate optimism. RESULTS AND LIMITATIONS: The unadjusted prevalence was 17.2% (n = 1763) for bladder cancer, 1.20% (n = 123) for UTUC, and 1.00% (n = 103) for renal cancer. The final model included predictors of increased risk (visible haematuria, age, smoking history, male sex, and family history) and reduced risk (previous haematuria investigations, urinary tract infection, dysuria/suprapubic pain, anticoagulation, catheter use, and previous pelvic radiotherapy). The area under the receiver operating characteristic curve of the final model was 0.86 (95% confidence interval 0.85-0.87). The model is limited to patients without previous urological malignancy. CONCLUSIONS: This cancer prediction model is the first to consider established and novel urinary tract cancer diagnostic markers. It can be used in secondary care for risk stratifying patients and aid the clinician's decision-making process in prioritising patients for investigation. PATIENT SUMMARY: We have developed a tool that uses a person's characteristics to determine the risk of cancer if that person develops blood in the urine (haematuria). This can be used to help prioritise patients for further investigation.
CitationEur Urol Focus. 2022 Jun 24:S2405-4569(22)00129-8. doi: 10.1016/j.euf.2022.06.001.
NoteSupports Open Access
Except where otherwise noted, this item's license is described as Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
Showing items related by title, author, creator and subject.
Did the 'Be Clear on Bowel Cancer' public awareness campaign pilot result in a higher rate of cancer detection? Bethune, Rob; Marshall, Morwena J.; Mitchell, S J; Oppong, C; Cartmel, M T; Arumugam, P J; Gee, A S; Daniels, Ian R. (BMJ, 2013-07)To assess the impact of a 7-week public bowel cancer awareness campaign pilot by reviewing the number of 2-week referrals from general practitioners (GPs) to hospital, endoscopic procedures and new cancers diagnosed ...
Clinical evidence of field cancerization in patients with oral cavity cancer in a betel quid chewing area. Liao, C-T; Wallace, Christopher G; Lee, L-Y; Hsueh, C; Lin, C-Y; Fan, K-H; Wang, H-M; Ng, S-H; Lin, C-H; Tsao, C-K; Chen, I-H; Huang, S-F; Kang, C-J; Yen, T-C (Elsevier, 2014-08)We sought to investigate whether there is evidence of field cancerization in patients with oral cavity squamous cell carcinoma (OSCC) enrolled in a betel quid chewing area. We also assessed whether betel quid chewing is ...
Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum Glynne-Jones, R.; Hava, N.; Goh, V.; Bosompem, S.; Bridgewater, J.; Chau, I.; Gaya, A.; Wasan, H.; Moran, B.; Melcher, L.; MacDonald, A.; Osborne, Melanie; Beare, S.; Jitlal, M.; Lopes, A.; Hall, M.; West, N.; Quirke, P.; Wong, W. L.; Harrison, M.; Bacchus, investigators (BioMed Central, 2015-10-23)BACKGROUND: In locally advanced rectal cancer (LARC) preoperative chemoradiation (CRT) is the standard of care, but the risk of local recurrence is low with good quality total mesorectal excision (TME), although many still ...